Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

357
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
357
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Auricularia auricula Polysaccharide Extracted Under Ultrahigh Pressure: Structural Characterization and Immunomodulatory Mechanism.

Journal of food science·2026
Same author

Placental toxic metal concentrations and preterm birth: Modification by social stressors.

Reproductive toxicology (Elmsford, N.Y.)·2026
Same author

Spermine oxidase-DOX conjugates reshape tumor microenvironment via carbonyl stress to potentiate bladder cancer chemotherapy.

Materials today. Bio·2026
Same author

A dihydrofuro[2,3-b] benzofuran derivative alleviates lipopolysaccharide induced acute lung injury <i>via</i> suppressing MAPK signaling.

Frontiers in pharmacology·2026
Same author

Exploring the CeRNA landscape in plants: advances, methods, and challenges.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2026
Same author

The pyruvate kinase activator etavopivat (FT-4202) limits pulmonary and systemic sequelae of sepsis in a mouse LPS model.

American journal of physiology. Lung cellular and molecular physiology·2026

Related Experiment Video

Updated: May 1, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K

Statistical considerations in biosimilar assessment using biosimilarity index.

Aijing Zhang1, Jung-Ying Tzeng1, Shein-Chung Chow1

  • 1Aijing Zhang is a graduate student, Jung-Ying Tzeng is an Associate Professor in the Department of Statistics at NC State University, Raleigh, NC 27695, Shein-Chung Chow is a Professor in the Department of Bioinformatics and Biostatistics at Duke University, Durham, NC 27708.

Journal of Bioequivalence & Bioavailability
|April 1, 2014
PubMed
Summary
This summary is machine-generated.

A novel biosimilarity index, based on reproducibility probability, assesses the similarity between biologic drugs. This method accounts for the inherent variability in complex biologic products, offering a robust approach to evaluating biosimilars.

Keywords:
Biosimilarity IndexDegree of SimilarityHighly SimilarReproducibility Probability

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.8K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

20.3K

Related Experiment Videos

Last Updated: May 1, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.8K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

20.3K

Area of Science:

  • Biopharmaceutical sciences
  • Drug development
  • Regulatory science

Background:

  • Biologic products face unique challenges during biosimilar development due to their complexity and manufacturing variability.
  • Unlike small molecule drugs, biosimilars are not exact copies and require specialized assessment methods.
  • Regulatory approval for biosimilars necessitates robust methods to demonstrate similarity to the reference biologic.

Purpose of the Study:

  • To propose and demonstrate a novel biosimilarity index for assessing the similarity between test and reference biologic products.
  • To provide a robust method that accounts for the inherent variability of complex biologic molecules.
  • To enable the quantitative assessment of the degree of similarity between biosimilars and their reference counterparts.

Main Methods:

  • Development of a biosimilarity index founded on reproducibility probability.
  • Establishment of a reference standard by comparing the reference product against itself.
  • Assessment of biosimilarity between test and reference products relative to the established reference standard.

Main Results:

  • The proposed biosimilarity index offers a robust framework for evaluating biosimilarity.
  • The method allows for a quantitative assessment of the degree of similarity between biologic products.
  • The approach is designed to be resilient to the inherent variabilities in biosimilar manufacturing.

Conclusions:

  • The biosimilarity index based on reproducibility probability is a viable and robust tool for assessing biosimilarity.
  • This approach addresses the challenges posed by the complexity and variability of biologic products.
  • The method facilitates a more precise and reliable evaluation of biosimilar products for regulatory approval.